Emera Incorporated EMA
51.13 USD +0.35 (+0.69%)
Regular-session close
51.13 0.00 0.00%
After hours · Nov 13, 5:25 PM ET
50.76 Day range 51.45
45.66 52-week range 55.11
- YTD
- +3.84%
- 1 year
- +5.60%
News
marketbeat.com Emera Q3 Earnings Call Highlights Emera TSE: EMA reported third-quarter adjusted earnings of C$260 million and outlined a C$21.5 billion, five-year capital plan, with most of the investment directed to its Florida utilities.
gurufocus.com Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta Vir Biotechnology, Inc. (Nasdaq: VIR), today announced positive topline results from the pivotal Phase 3 ECLIPSE 1 trial evaluating monthly subcutaneous adminis
gurufocus.com Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data Vir Biotechnology, Inc. (Nasdaq: VIR), today announced new, expanded data from the Phase 2 SOLSTICE trial evaluating monthly subcutaneous administration of eleb
benzinga.com Emera Sees 2026 Adjusted EPS Growth Above 5%-7% Target Range; Maintains 5%-7% Annual Adjusted EPS Growth Target Through 2030 Emera (TSX:EMA) expect to deliver 2026 adjusted EPS growth above its annual target range of 5%-7%, while maintaining its target of 5%-7% annual adjusted EPS growth through 2030.- benzinga.com Emera Q3 Adj. EPS C$0.85 Misses C$0.93 Estimate, Sales C$1.984B Miss C$2.000B Estimate Emera (TSX:EMA) reported quarterly earnings of C$0.85 per share which missed the analyst consensus estimate of C$0.93 by 8.6 percent. This is a 3.41 percent decrease over earnings of C$0.88 per share…
benzinga.com Emera Q3 Adj. EPS C$0.85 Misses C$0.93 Estimate Emera (TSX:EMA) reported quarterly earnings of $0.85 per share which missed the analyst consensus estimate of $0.93 by 8.6 percent. This is a 3.41 percent decrease over earnings of $0.88 per share…
benzinga.com Enbridge, Moderna On Deck Friday As Demand, Vaccine Pipeline Face Test Enbridge headlines Friday’s reports, with investors weighing whether resilient pipeline utilization can offset a softer revenue comparison. Moderna, Brookfield Asset Management, Humana, Vistra, PPL,…
benzinga.com Barclays Maintains Equal-Weight on Emera, Lowers Price Target to $50 Barclays analyst Nicholas Campanella maintains Emera (NYSE:EMA) with a Equal-Weight and lowers the price target from $53 to $50.